On November 22, 2021, BeiGene announced that the first patient in a phase 1 clinical trial of the potent tyrosine kinase 2 (TYK2) inhibitor BGB-23339 under investigation has been administered
As a highly selective allosteric TYK2 inhibitor, BGB-23339 has shown effective inhibition of pro-inflammatory cytokines in preclinical studies, and is expected to be used in the treatment of diseases such as psoriasis and inflammatory bowel disease
The press release stated that this is BeiGene's first internally developed candidate therapy for inflammation and immune diseases
TYK2 is a member of the Janus kinase (JAK) family of proteins.
It is an intracellular signal kinase that mediates interleukin (IL)-23, IL-12 and type I interferon signal transduction
It plays an important role in transmitting inflammation and immune response signals, and is considered to be related to the pathology of a variety of immune-mediated diseases
BGB-23339 is a highly selective allosteric TYK2 inhibitor
It is designed to target the regulatory pseudokinase (JH2) domain on TYK2.
It has shown strong selectivity in preclinical studies and can effectively inhibit pro-inflammatory cytokines such as IL-12, IL-23 and type I IFN.
Its phase 1 clinical trial aims to evaluate the safety, tolerability, pharmacokinetics and preliminary activity of BGB-23339, and it is expected that 115 healthy volunteers will be enrolled
 BeiGene Initiates First-in-Human Phase1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339.
Retrieved November 22, 2021, from https:// original text has been deleted)